Abstract The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the present report the in vitro antiviral activity end-points are analyzed from the pharmacokinetic perspective. The available pharmacokinetic data from clinically relevant and excessive dosing studies indicate that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans.

中文翻译：

---

从药代动力学的角度来看，伊维菌素是一种潜在的 COVID-19 治疗方法：已知给药方案不可能达到抗病毒水平

摘要 最近发现广谱抗寄生虫药伊维菌素可在体外抑制 SARS-CoV-2，并被提议作为 COVID-19 药物再利用的候选药物。在本报告中，从药代动力学角度分析了体外抗病毒活性终点。来自临床相关和过量给药研究的可用药代动力学数据表明，人类不太可能达到 SARS-CoV-2 抑制浓度。